Anika Therapeutics (ANIK) Capital Expenditures Growth (1y) (2011 - 2026)
Anika Therapeutics (ANIK) Capital Expenditures Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.06 Bn | 87.19 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.81 Bn | 32.07 Bn | 1.97 Bn | 32.28% |
| 3 | Zoetis | 32.50 Bn | 30.56 Bn | 1.62 Bn | -38.20% |
| 4 | Takeda Pharmaceutical | 27.51 Bn | 23.45 Bn | 4.39 Bn | -15.72% |
| 5 | United Therapeutics | 23.19 Bn | 21.04 Bn | 648.10 Mn | 32.98% |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.47 Bn | 1.16 Bn | -6.34% |
| 8 | Neurocrine Biosciences | 17.72 Bn | 16.40 Bn | 800.70 Mn | -86.92% |
| 9 | Elanco Animal Health | 12.56 Bn | 12.13 Bn | 785.00 Mn | -21.54% |
| 10 | Anika Therapeutics | 203.03 Mn | 136.24 Mn | 19.00 Mn | -89.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -89.04% |
| Dec 31, 2025 | 1,203.26% |
| Sep 30, 2025 | 16.45% |
| Jun 30, 2025 | -17.43% |
| Mar 31, 2025 | -19.29% |
| Dec 31, 2024 | -71.68% |
| Sep 30, 2024 | -244.40% |
| Jun 30, 2024 | 445.30% |
| Mar 31, 2024 | -55.22% |
| Dec 31, 2023 | -75.06% |
| Sep 30, 2023 | 716.61% |
| Jun 30, 2023 | -105.73% |
| Mar 31, 2023 | 4.75% |
| Dec 31, 2022 | 554.66% |
| Sep 30, 2022 | -144.55% |
| Jun 30, 2022 | -129.88% |
| Mar 31, 2022 | 132.63% |
| Dec 31, 2021 | 4,274.07% |
| Sep 30, 2021 | 248.61% |
| Jun 30, 2021 | 153.46% |